

Change of Auditor

29 May 2026

Epiminder Limited (ASX:EPI) (**Epiminder** or the **Company**) announces that following a formal evaluation process of external audit services, the Board has resolved to appoint **Ernst & Young (EY)** as the Company's auditor with effect from 1 July 2026, being the commencement of the financial year ending 30 June 2027 (FY27).

The appointment of EY is subject to the Australian Securities and Investments Commission (ASIC) granting its consent to the resignation of the current auditor, **MVAB Audit Pty Ltd (MVAB Audit)**, in accordance with section 329(5) of the *Corporations Act 2001* (Cth). The Board thanks MVAB Audit for their professional services and support during their tenure.

A resolution will be proposed at the Company's next Annual General Meeting to confirm the appointment of the Company's auditor.

Authorisation

This announcement has been authorised for lodgement to the ASX by Epiminder's Company Secretary.

Investor & Media Enquiries: investors@epiminder.com

About Epiminder

Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.

Minder's long-term monitoring of patients outside a controlled clinical environment provides clinicians with the data needed to remotely monitor and assess the patient's underlying condition, including the effectiveness of drug therapies and other interventions.

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.